search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Industry News


Catalent and Trizell in advanced cell therapy manufacturing agreement


C


atalent Cell & Gene Therapy has signed an agreement with Trizell GmbH to support the


manufacturing of Trizell’s Phase 1 cell therapy for the treatment of micro- and macroangiopathies. Trizell’s therapeutic is an advanced therapy medicinal product (ATMP) and using a regulatory macrophages platform technology and initial development work for the product will take place at the University Medical Center Schleswig Holstein (UKSH),


Department of Anesthesiology and Intensive Care Medicine, the Clinic for Applied Cellular Medicine, and the Department of Cardiovascular Surgery, in collaboration with Catalent.


CGMP manufacturing of the cell therapy will take place at Catalent’s facility in Gosselies, Belgium, a 25,000 square-foot (2,300 square metre) facility that provides development and clinical GMP manufacturing services. Construction is in progress at the site on a dedicated 60,000


square-foot (5,574 square-metre) adjacent commercial-scale production and fill-finish facility, which is scheduled to open in 2022. Catalent Cell & Gene Therapy has extensive experience in viral vector process development, scale-up and manufacturing and is a full-service partner for adeno-associated virus (AAV), lentiviral vectors and CAR-T immunotherapies and when it acquired Bone Therapeutics’ MaSTherCell facilities in


Gosselies added expertise in autologous and allogeneic cell therapy development and CGMP manufacturing, enabling it to provide manufacturing support for innovators across the entire field of advanced biotherapeutics. Trizell GmbH is a German biotech company focusing on the research, development, production and distribution of innovative pharmaceutical and diagnostic products in particular in the field of gene therapy and cell therapy.


Deep Branch closes €8 million Series A funding round


Carbon dioxide recycling company Deep Branch has completed an


€8 million Series A investment round complementing a combined


€4 million in non-dilutive funding secured from UK and EU grant- funded projects scheduled from Q4 2020 to Q1 2023. Novo


Airedale Chemical has implemented a plan to develop its own water supply to cut running costs and maintain the environment by drilling a 20-metre deep borehole within its grounds in order to test the quality of the water that will be used in the company’s chemical processing works. The company plans to become fully water self- sufficient by the end of the year. Airedale Chemical’s operations


director, Daniel Fox, commented: “As a chemical company we take our environmental responsibilities very seriously so when the opportunity arose for us to source the water used in our chemical processing from within our existing boundaries we jumped at the chance. We’re outsourcing 30% less water which aids water conservation and we’re also


10


Holdings and DSM Venturing led the new round, with participation from Total Carbon Neutrality Ventures and Barclays Sustainable Impact Capital. Johan Hueffer, Senior Partner at Novo Holdings, and Rob Beudeker, Investment Director at DSM Venturing, will join


Deep Branch’s Board of Directors. Lars Topholm, Head of Research at Carnegie Investment Bank in Denmark and non-executive Board member of Deep Branch since 2019, has been elected Chair of the Board.


Deep Branch addresses both


the sustainability of animal farming and the reduction of carbon dioxide emissions with its CO2


-to-


protein technology, which it says creates the first scalable path for a “truly sustainable” protein generation process from a waste product.


Airedale Chemical drills down to aid water conservation


Chris Chadwick, Managing Director at Airedale Chemical: working with the Environment Agency on reducing the company’s carbon footprint.


working on becoming entirely self-sufficient for water in the next 12 months.”


Airedale Chemical won a Green


Apple Award for Environmental Best Practice and a gold award


in the Zero Waste Awards for its ‘Zero to Landfill’ scheme which completely cut out site waste destined for landfill, instead recycling waste for use in energy production and community projects. Managing director Chris Chadwick, added: “We will be able to reduce the amount of drinking-quality water we use on site and reduce our overall carbon footprint without having to expand the site. All of this will be concealed beneath a single manhole cover so there will be no visual impact for our neighbours. We have been working closely with the Environment Agency to ensure the correct licensing and practices are in place and they will continue to monitor and inspect the operation to ensure all standards are met.”


March/April 2021 • Issue 2


www.chemicalsknowledgehub.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64